Kiniksa’s One-Drug Engine Just Beat Again — ARCALYST Revenue Up 55%, Guidance Raised

Kiniksa Pharmaceuticals beat on revenue and raised its full-year outlook, powered by a single blockbuster drug: ARCALYST, the first and only FDA-approved therapy for recurrent pericarditis. The result showed a focused, cash-generative commercial engine still growing fast. On July 28, $KNSA — Kiniksa Pharmaceuticals — reported second-quarter results that beat expectations and lifted the company’s […]

Lockheed Martin Just Hit a Record $230B Backlog — and Raised Its Guidance to Match

Lockheed Martin beat on earnings, raised its full-year outlook, and pushed its order backlog to a record $230 billion. For the world’s largest defense contractor, this was a quarter that showed demand — and cash flow — accelerating. When the biggest defense company on earth beats expectations and raises its outlook and reports a record […]